The usefulness of arbekacin compared to vancomycin

J-H Hwang; J-H Lee; M-K Moon; J-S Kim; K-S Won; C-S Lee

doi:10.1007/s10096-011-1490-9

The usefulness of arbekacin compared to vancomycin

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1663-6. doi: 10.1007/s10096-011-1490-9. Epub 2011 Nov 29.

Authors

J-H Hwang¹, J-H Lee, M-K Moon, J-S Kim, K-S Won, C-S Lee

Affiliation

¹ The Department of Pharmacy, Chonbuk National University Hospital, and The Department of Preventive Medicine, Chonbuk National University Medical School, Jeonju, Jeonbuk, South Korea.

Abstract

The bacteriological efficacy response (improved, arbekacin vs. vancomycin; 71.2% vs. 79.5%) and clinical efficacy response (improved, arbekacin vs. vancomycin; 65.3% vs. 76.1%) were not statistically different between the two groups. The complication rate was significantly higher in the vancomycin group (32.9%) compared to the arbekacin group (15.1%) (p=0.019). Arbekacin was not inferior to vancomycin, and it could be a good alternative drug for vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) treatment.

Publication types

Comparative Study

MeSH terms

Adult
Anti-Bacterial Agents / administration & dosage*
Case-Control Studies
Dibekacin / administration & dosage
Dibekacin / analogs & derivatives*
Female
Humans
Male
Methicillin-Resistant Staphylococcus aureus / drug effects
Methicillin-Resistant Staphylococcus aureus / isolation & purification*
Middle Aged
Retrospective Studies
Staphylococcal Infections / complications
Staphylococcal Infections / drug therapy*
Staphylococcal Infections / microbiology
Treatment Outcome
Vancomycin / administration & dosage*

Substances

Anti-Bacterial Agents
Dibekacin
Vancomycin
arbekacin